cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
Company profile
Ticker
CUE
Exchange
Website
CEO
Daniel Passeri
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Imagen Biopharma, Inc.
SEC CIK
Corporate docs
Subsidiaries
Cue Biopharma Securities Corp. ...
CUE stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
28 Mar 24
10-Q
2023 Q3
Quarterly report
3 Nov 23
8-K
Departure of Directors or Certain Officers
14 Sep 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
EFFECT
Notice of effectiveness
30 May 23
CORRESP
Correspondence with SEC
24 May 23
UPLOAD
Letter from SEC
16 May 23
S-3
Shelf registration
9 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
Transcripts
CUE
Earnings call transcript
2023 Q4
8 Apr 24
CUE
Earnings call transcript
2023 Q3
9 Nov 23
CUE
Earnings call transcript
2023 Q2
9 Aug 23
CUE
Earnings call transcript
2022 Q4
21 Mar 23
CUE
Earnings call transcript
2022 Q3
15 Nov 22
CUE
Earnings call transcript
2022 Q2
24 Aug 22
CUE
Earnings call transcript
2021 Q2
18 Aug 21
CUE
Earnings call transcript
2021 Q1
18 May 21
CUE
Earnings call transcript
2020 Q4
17 Mar 21
CUE
Earnings call transcript
2020 Q2
1 Sep 20
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 54.84 mm | 54.84 mm | 54.84 mm | 54.84 mm | 54.84 mm | 54.84 mm |
Cash burn (monthly) | (no burn) | (no burn) | 3.81 mm | 4.43 mm | 2.60 mm | 3.29 mm |
Cash used (since last report) | n/a | n/a | 26.20 mm | 30.51 mm | 17.90 mm | 22.67 mm |
Cash remaining | n/a | n/a | 28.64 mm | 24.33 mm | 36.94 mm | 32.17 mm |
Runway (months of cash) | n/a | n/a | 7.5 | 5.5 | 14.2 | 9.8 |
Institutional ownership, Q3 2023
28.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 74 |
Opened positions | 11 |
Closed positions | 13 |
Increased positions | 25 |
Reduced positions | 15 |
13F shares | Current |
---|---|
Total value | 31.98 bn |
Total shares | 14.01 mm |
Total puts | 31.00 k |
Total calls | 25.70 k |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
Slate Path Capital | 2.40 mm | $5.53 bn |
BLK Blackrock | 2.13 mm | $4.90 bn |
Vanguard | 2.12 mm | $4.89 bn |
Geode Capital Management | 762.42 k | $1.75 bn |
Bleichroeder | 755.03 k | $1.74 bn |
STT State Street | 698.20 k | $1.61 bn |
Dimensional Fund Advisors | 566.61 k | $1.30 bn |
Robertson Stephens Wealth Management | 478.50 k | $1.10 bn |
Monaco Asset Management SAM | 359.74 k | $827.40 mm |
Sanders Morris Harris | 346.21 k | $713.43 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Mar 24 | Daniel R Passeri | Stock Option Common Stock | Grant | Acquire A | No | No | 1.94 | 400,000 | 776.00 k | 400,000 |
6 Mar 24 | Matteo Levisetti | Stock Option Common Stock | Grant | Acquire A | No | No | 1.94 | 260,000 | 504.40 k | 260,000 |
6 Mar 24 | Colin Sandercock | Stock Option Common Stock | Grant | Acquire A | No | No | 1.94 | 175,000 | 339.50 k | 175,000 |
6 Mar 24 | Suri Anish | Stock Option Common Stock | Grant | Acquire A | No | No | 1.94 | 300,000 | 582.00 k | 300,000 |
6 Mar 24 | Kerri-Ann Millar | Stock Option Common Stock | Grant | Acquire A | No | No | 1.94 | 250,000 | 485.00 k | 250,000 |
News
Forecasting The Future: 4 Analyst Projections For Cue Biopharma
9 Apr 24
Stifel Maintains Buy on Cue Biopharma, Maintains $8 Price Target
9 Apr 24
Oppenheimer Maintains Outperform on Cue Biopharma, Maintains $10 Price Target
9 Apr 24
Cue Biopharma Q1 EPS $(0.28) Misses $(0.27) Estimate, Sales $1.82M Beat $1.13M Estimate
8 Apr 24
Piper Sandler Reiterates Overweight on Cue Biopharma, Maintains $8 Price Target
3 Apr 24